Therefore, larger studies with well-powered AD patient cohorts may be needed to more robustly assess the prevalence of autoantibodies selectively targeting brain-derived tau and to clarify their potential association with neurodegeneration. This evidence concerns the gene MAPT and Alzheimer disease.